Menarini Group Welcomes Thomas Cueni as New Board Member to Enhance Governance

Menarini Group Welcomes Thomas Cueni as New Board Member

On May 7, 2026, Menarini Group, a multinational pharmaceutical company headquartered in Florence, Italy, announced the appointment of seasoned executive Thomas Cueni to its Board of Directors. This strategic move is aimed at reinforcing the governance structure of the company, ensuring that it continues to lead in the ever-evolving pharmaceutical landscape.

Thomas Cueni brings with him nearly four decades of international experience in the pharmaceutical sector. He has held significant positions, including serving as the Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and as a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Throughout his career, Cueni has been instrumental in spearheading cross-sector initiatives designed to enhance patient access to treatments for chronic diseases and to shape policies addressing global health challenges, such as the COVID-19 pandemic.

In a notable achievement, Cueni established an AMR Action Fund that amassed nearly a billion dollars to promote the development of new antibiotics. He is also the founding chair of the AMR Industry Alliance, one of the largest coalitions in the private sector created to deliver sustainable solutions to combat antimicrobial resistance. His unparalleled expertise in health policy aligns seamlessly with Menarini's mission to integrate innovation and accountability in healthcare.

Upon accepting his new role, Cueni expressed enthusiasm about joining a dynamic company dedicated to scientific excellence and innovation. He stated, “I am proud to bring my experience and commitment to Menarini. Joining a growing company that focuses on global health improvement represents a unique opportunity for me to contribute to enhancing the lives of patients everywhere.”

This sentiment was echoed by Menarini's shareholders and board members, Lucia and Alberto Giovanni Aleotti, who highlighted Cueni’s vast experience in global health policy as a direct fit with Menarini's mission. They noted that his appointment not only strengthens their leadership but also enhances the organization’s capacity to address the challenges facing the pharmaceutical industry in an increasingly complex geopolitical context. They also took a moment to express sincere gratitude to Jürg Witmer, who served on the board for 13 years, for his passion and commitment to the company.

Menarini, which operates in 140 countries and has a consolidated revenue of €4.88 billion, focuses on major treatment areas such as cardiometabolism, oncology, gastroenterology, pulmonology, and anti-inflammatory/analgesic products. The company is committed to maintaining the highest quality standards through its continuous investment in research and development, further contributing to global health initiatives.

This leadership change comes at a critical time as the pharmaceutical industry faces unprecedented challenges while trying to adapt to new demands and innovations within the healthcare sector. With Thomas Cueni on board, Menarini Group is poised to strengthen its governance strategy and make a significant impact in improving patient care across the globe.

For more information about Menarini and its initiatives, visit Menarini's official website.